Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UO4B
|
|||
| Former ID |
DNCL001590
|
|||
| Drug Name |
RQ-00000005
|
|||
| Synonyms |
Capromorelin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Frailty [ICD-11: MG2A; ICD-10: R54] | Phase 2 | [1] | |
| Company |
RaQualia Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H35N5O4
|
|||
| Canonical SMILES |
CC(C)(C(=O)NC(COCC1=CC=CC=C1)C(=O)N2CCC3=NN(C(=O)C3(C2)CC4=CC=CC=C4)C)N
|
|||
| InChI |
1S/C28H35N5O4/c1-27(2,29)25(35)30-22(18-37-17-21-12-8-5-9-13-21)24(34)33-15-14-23-28(19-33,26(36)32(3)31-23)16-20-10-6-4-7-11-20/h4-13,22H,14-19,29H2,1-3H3,(H,30,35)/t22-,28-/m1/s1
|
|||
| InChIKey |
KVLLHLWBPNCVNR-SKCUWOTOSA-N
|
|||
| CAS Number |
CAS 193273-66-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Growth hormone secretagogue receptor 1 (GHSR) | Target Info | Agonist | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00527046) Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults. U.S. National Institutes of Health. | |||
| REF 2 | Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor. Br J Pharmacol. 2014 Mar;171(5):1275-86. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.